Literature DB >> 25737571

Reliability of Apnea-Hypopnea Index Measured by a Home Bi-Level Pressure Support Ventilator Versus a Polysomnographic Assessment.

Marjolaine Georges1, Dan Adler1, Olivier Contal1, Fabrice Espa2, Stephen Perrig2, Jean-Louis Pépin3, Jean-Paul Janssens4.   

Abstract

BACKGROUND: Ventilators designed for home care provide clinicians with built-in software that records items such as compliance, leaks, average tidal volume, total ventilation, and indices of residual apnea and hypopnea. Recent studies have showed, however, an important variability between devices regarding reliability of data provided. In this study, we aimed to compare apnea-hypopnea indices (AHI) provided by home ventilators (AHINIV) versus data scored manually during polysomnography (AHIPSG) in subjects on noninvasive ventilation (NIV) for obesity-hypoventilation syndrome.
METHODS: Stable subjects with obesity-hypoventilation syndrome on NIV, all using the same device, underwent 3 consecutive polysomnographic sleep studies with different backup breathing frequencies (spontaneous mode, low and high backup breathing frequencies). During each recording, AHINIV was compared with AHIPSG.
RESULTS: Ten subjects (30 polysomnogram tracings) were analyzed. For each backup breathing frequency (spontaneous mode, low and high backup breathing frequencies), AHI values were 62 ± 7/h, 26 ± 7/h, and 17 ± 5/h (mean ± SD), respectively. Correlation between AHINIV and AHIPSG was highly significant (r(2) = 0.89, P < .001). As determined by Bland-Altman analysis, mean bias was 6.5 events/h, and limits of agreement were +26.0 and -12.9 events/h. Bias increased significantly with higher AHI values. Using a threshold AHI value of 10/h to define appropriate control of respiratory events, the ventilator software had a sensitivity of 90.9%, a specificity and positive predictive value of 100%, and a negative predictive value of 71%.
CONCLUSIONS: In stable subjects with obesity-hypoventilation syndrome, the home ventilator software tested was appropriate for determining if control of respiratory events was satisfactory on NIV or if further testing or adjustment of ventilator settings was required. (ClinicalTrials.gov registration NCT01130090.).
Copyright © 2015 by Daedalus Enterprises.

Entities:  

Keywords:  apnea-hypopnea index; home ventilator software; monitoring; noninvasive ventilation; obesity-hypoventilation syndrome

Mesh:

Year:  2015        PMID: 25737571     DOI: 10.4187/respcare.03633

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  5 in total

1.  And the Doctor Answers: "Dream, Dream, I Will Be the Guardian of Your Breathing…".

Authors:  Claudio Rabec; Jésus Gonzalez-Bermejo; Christophe Perrin; Bruno Langevin; Jean-Louis Pepin; Daniel Rodenstein; Jean Paul Janssens
Journal:  J Clin Sleep Med       Date:  2016-08-15       Impact factor: 4.062

Review 2.  Monitoring Long Term Noninvasive Ventilation: Benefits, Caveats and Perspectives.

Authors:  Jean-Paul Janssens; Chloé Cantero; Patrick Pasquina; Marjolaine Georges; Claudio Rabec
Journal:  Front Med (Lausanne)       Date:  2022-05-19

3.  Switch of noninvasive ventilation (NIV) to continuous positive airway pressure (CPAP) in patients with obesity hypoventilation syndrome: a pilot study.

Authors:  Sarah Orfanos; Dany Jaffuel; Christophe Perrin; Nicolas Molinari; Pascal Chanez; Alain Palot
Journal:  BMC Pulm Med       Date:  2017-03-14       Impact factor: 3.317

4.  Prediction of severe acute exacerbation using changes in breathing pattern of COPD patients on home noninvasive ventilation.

Authors:  Sophie Blouet; Jasmine Sutter; Emeline Fresnel; Adrien Kerfourn; Antoine Cuvelier; Maxime Patout
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-08-27

Review 5.  Setting up home noninvasive ventilation.

Authors:  Jean-Michel Arnal; Charles-Philippe Thevenin; Benoit Couzinou; Joelle Texereau; Aude Garnero
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.